Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII

News provided by

Nov 30, 2023, 07:00 ET

DALLAS, Nov. 30, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Jared Stephens, PhD, Vice President of Strategy and Business Development, will present at the 13^th Annual Ophthalmology Innovation Summit (OIS) taking place from December 1-2 in San Diego, California. Details for the presentation are as follows:

Title: Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration

Session Title: Retina Innovation Showcase
Session Date: December 2, 2023
Session Time: 11:05 a.m. E.T.
Location: Omni Hotel San Diego
Presenter: Jared Stephens, PhD, Vice President of Strategy and Business Development

During his presentation, Dr. Stephens will provide a corporate update on Nanoscope's recent and upcoming activities.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company's lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
[email protected]

SOURCE Nanoscope Therapeutics